Acute Neuromuscular Respiratory Failure

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Acute Neuromuscular Respiratory Failure

Key Takeaways Explain This Topic AI

Assess the clinical respiratory trajectory, bulbar function, cough, secretions, and serial mechanics; normal saturation does not exclude impending failure.

FVC around 20 mL/kg, NIF less negative than −30 cm H2O, and low expiratory pressure are warning values rather than automatic standalone intubation criteria.

Myasthenic crisis requires respiratory support, trigger treatment, medication review, and rapid immunotherapy with PLEX or IVIG.

GBS is treated with IVIG or plasma exchange when indicated; corticosteroids do not treat the neuropathy, and succinylcholine risks severe hyperkalemia.

Preserved sensory responses with myopathic motor units supports CIM, while reduced sensory and motor amplitudes supports CIP; mixed disease is common.

Last updated: October 2026

Acute Neuromuscular Respiratory Failure

Acute neuromuscular respiratory failure ( A N R F ANRF A NRF ) represents a true neurocritical emergency where failure of the peripheral nervous system, neuromuscular junction, or muscle compromises alveolar ventilation, airway patency, and pulmonary clearance. Unlike primary pulmonary parenchymal diseases (such as pneumonia or A R D S ARDS A R D S ) where gas exchange failure produces early hypoxemia, neuromuscular weakness produces an insidious failure of the respiratory bellows that culminates in sudden, unexpected asphyxia if not proactively identified.

Pathophysiology: The Three Functional Muscle Compartments

Neuromuscular respiratory failure results from weakness distributed across three distinct anatomical muscle compartments:

Inspiratory Muscle Compartment (The Respiratory Pump): The diaphragm (innervated by the phrenic nerves, C 3 – C 5 C3\text{--}C5 C 3 – C 5 ) generates 70 – 80 % 70\text{--}80\% 70 – 80% of resting tidal volume, supported by the external intercostal and accessory muscles (sternocleidomastoids, scalenes). Diaphragmatic weakness causes progressive reductions in tidal volume, leading to diffuse microatelectasis, decreased thoracic compliance, ventilation-perfusion ( V / Q V/Q V / Q ) mismatch, and rapid shallow compensatory breathing.

Expiratory Muscle Compartment (The Cough Mechanism): The abdominal wall muscles (rectus abdominis, transversus abdominis, internal and external obliques) and internal intercostal muscles power active expiration. Peak cough flow ( P C F PCF PCF ) drops below the critical threshold of 160 L/min 160\text{ L/min} 160 L/min , abolishing the kinetic energy needed to expel bronchial secretions. This leads to retained secretions, mucous plugging, lobar atelectasis, and secondary bacterial bronchopneumonia.

Bulbar Muscle Compartment (Airway Protection & Patency): Cranial nerves IX, X, and XII control pharyngeal, laryngeal, and tongue musculature. Weakness produces severe dysphagia, pooling of oropharyngeal secretions, loss of laryngeal adductor closure reflexes, recurrent micro-aspiration, and acute upper airway collapse during inspiration.

Muscle Compartment Primary Innervation & Muscles Clinical Hallmarks of Failure Objective Bedside Metric

Inspiratory Pump Phrenic nerve ( C 3 – C 5 C3\text{--}C5 C 3 – C 5 ); diaphragm, external intercostals, scalenes Orthopnea, tachypnea with shallow tidal volumes, paradoxical abdominal breathing Forced Vital Capacity ( F V C < 20 mL/kg FVC < 20\text{ mL/kg} F V C < 20 mL/kg );; Negative Inspiratory Force ( N I F > − 30 cmH 2 O NIF > -30\text{ cmH}_2\text{O} N I F > − 30 cmH 2 ​ O )

Expiratory Cough Thoracic nerves ( T 7 – L 1 T7\text{--}L1 T 7 – L 1 ); rectus abdominis, internal/external obliques Inability to clear secretions, wet gurgling cough, progressive basilar atelectasis Positive Expiratory Pressure ( P E P < 40 cmH 2 O PEP < 40\text{ cmH}_2\text{O} PEP < 40 cmH 2 ​ O );; Peak Cough Flow ( P C F < 160 L/min PCF < 160\text{ L/min} PCF < 160 L/min )

Bulbar / Airway Cranial nerves IX, X, XII; soft palate, pharyngeal constrictors, tongue Dysphonia, nasal speech, saliva pooling, coughing while swallowing liquids Single-breath count < 20 < 20 < 20 ;; Loss of gag reflex, stertorous inspiratory stridor

Bedside Pulmonary Monitoring & The "20/30/40 Rule"

In acute neuromuscular disease, routine clinical signs—such as pulse oximetry and physical inspection—grossly underestimate the severity of diaphragmatic exhaustion. Obtain serial respiratory mechanics at a frequency appropriate to progression, alongside bulbar function, cough, secretions, fatigue, and gas exchange. Facial weakness, poor seal, and cooperation can affect results.

The Standardized "20/30/40 Rule"

Concern for respiratory failure increases when respiratory parameters cross the commonly used 20/30/40 warning values , interpreted with the clinical trajectory:

Forced Vital Capacity (FVC): Normal is 60 – 70 mL/kg 60\text{--}70\text{ mL/kg} 60 – 70 mL/kg . An F V C < 20 mL/kg FVC < 20\text{ mL/kg} F V C < 20 mL/kg (or a rapid drop of ≥ 50 % \ge 50\% ≥ 50% over 24 hours) indicates severe loss of sigh mechanism and impending pump failure.

Negative Inspiratory Force (NIF) / Maximum Inspiratory Pressure (MIP): Normal is − 70 to − 100 cmH 2 O -70\text{ to } -100\text{ cmH}_2\text{O} − 70 to − 100 cmH 2 ​ O . A N I F NIF N I F worse than − 30 cmH 2 O -30\text{ cmH}_2\text{O} − 30 cmH 2 ​ O (i.e., between 0 0 0 and − 30 cmH 2 O -30\text{ cmH}_2\text{O} − 30 cmH 2 ​ O , such as − 20 cmH 2 O -20\text{ cmH}_2\text{O} − 20 cmH 2 ​ O ) indicates severe diaphragmatic fatigue and inability to generate negative pleural pressure.

Positive Expiratory Pressure (PEP) / Maximum Expiratory Pressure (MEP): Normal is > 100 cmH 2 O > 100\text{ cmH}_2\text{O} > 100 cmH 2 ​ O . A P E P < 40 cmH 2 O PEP < 40\text{ cmH}_2\text{O} PEP < 40 cmH 2 ​ O indicates expiratory muscle weakness insufficient to generate an effective cough.

Neck flexor weakness: This can accompany generalized respiratory muscle weakness but is not an exact anatomic surrogate for diaphragm function. Combine it with the rest of the respiratory assessment.

Warning

Normal saturation or a relatively normal arterial gas does not exclude impending neuromuscular respiratory failure. Hypercapnia may be late. Escalate according to the combined trajectory of mechanics, fatigue, bulbar protection, secretions, and examination; do not wait for a particular gas threshold or assume that every hypercapnic patient is minutes from arrest.

Myasthenia Gravis (MG) Crisis

Myasthenia Gravis ( M G MG MG ) is an autoimmune disorder of neuromuscular transmission caused by pathogenic autoantibodies targeting components of the post-synaptic neuromuscular junction: acetylcholine receptors ( A C h R AChR A C h R , 85 % 85\% 85% ) , muscle-specific kinase ( M u S K MuSK M u S K , 5 – 8 % 5\text{--}8\% 5 – 8% ) , or lipoprotein receptor-related protein 4 ( L R P 4 LRP4 L RP 4 , 1 – 3 % 1\text{--}3\% 1 – 3% ) .

Myasthenic Crisis vs. Cholinergic Crisis

Myasthenic Crisis: Severe, life-threatening exacerbation of myasthenic weakness involving respiratory and bulbar muscles requiring mechanical ventilation or non-invasive ventilatory support. Precipitated by infection ( 40 – 50 % 40\text{--}50\% 40 – 50% of cases), surgery, physical trauma, pregnancy, or tapering of immunotherapy.

Cholinergic Crisis (Historical): Overmedication with acetylcholinesterase inhibitors ( A C h E -Is AChE\text{-Is} A C h E -Is ) causing excessive accumulation of acetylcholine at muscarinic and nicotinic synapses. Presents with the SLUDGE syndrome : S alivation, L acrimation, U rination, D efecation, G astrointestinal cramping, and E mesis, accompanied by miosis, severe bronchorrhea, and muscle fasciculations.

Critical Pharmacological Triggers

Numerous common medications impair neuromuscular junction transmission and can instantly trigger myasthenic crisis:

Antibiotics: Aminoglycosides (gentamicin, amikacin, tobramycin—inhibit presynaptic ACh release); Fluoroquinolones (ciprofloxacin, levofloxacin—post-synaptic neuromuscular blockade); Macrolides (azithromycin, erythromycin).

Cardiovascular Drugs: Beta-blockers (propranolol, metoprolol); Calcium channel blockers; Class IA/IC antiarrhythmics (procainamide, quinidine).

Neuromuscular Blockers: Both depolarizing and non-depolarizing agents.

Magnesium sulfate: Can impair neuromuscular transmission. Avoid unnecessary exposure; a competing urgent indication requires expert risk assessment and respiratory monitoring.

Immune Checkpoint Inhibitors: Anti-PD-1 / anti-CTLA-4 agents (pembrolizumab, nivolumab) trigger severe, high-fatality autoimmune myocarditis paired with fulminant myasthenia gravis.

Review pyridostigmine: It is commonly held temporarily during intubated crisis to reduce secretions, then reintroduced during recovery. ICU admission alone does not require stopping it in every patient. Distinguish drug toxicity, infection, and worsening myasthenia, and review all medications.

Guillain-Barré Syndrome (GBS)

Guillain-Barré Syndrome ( G B S GBS GBS ) is an acute, post-infectious, immune-mediated polyradiculoneuropathy characterized by rapidly progressive, symmetrical ascending flaccid tetraparesis and areflexia. Approximately 25 – 30 % 25\text{--}30\% 25 – 30% of patients develop acute neuromuscular respiratory failure requiring mechanical ventilation.

Clinical Variants & Molecular Mimicry

Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Most common form in North America/Europe ( 85 % 85\% 85% ); autoimmune T-cell and complement attack against the Schwann cell myelin sheath.

Acute Motor Axonal Neuropathy (AMAN) & AMSAN: Direct antibody- and complement-mediated destruction of the axolemma at the nodes of Ranvier. Strongly linked to antecedent Campylobacter jejuni enteritis through molecular mimicry : surface lipooligosaccharides ( L O S LOS L OS ) of C. jejuni share identical molecular mimic epitopes with human gangliosides GM1 and GD1a .

Miller Fisher Syndrome (MFS): A distinctive variant characterized by the classic clinical triad of acute ophthalmoplegia, ataxia, and areflexia . Over 90 % 90\% 90% of patients harbor serum antibodies against ganglioside GQ1b , which is densely concentrated in the paranodal regions of cranial nerves III, IV, and VI and muscle spindle primary afferents.

Diagnostic Hallmarks: CSF Albuminocytological Dissociation

The classic cerebrospinal fluid finding is albuminocytological dissociation : an elevated CSF total protein (often > 100 – 300 mg/dL > 100\text{--}300\text{ mg/dL} > 100 – 300 mg/dL ) paired with a normal CSF white blood cell count ( < 5 cells/ μ L < 5\text{ cells/}\mu\text{L} < 5 cells/ μ L ). Crucially, CSF protein is often normal during the first 48 to 72 hours of illness and peaks only after 1 to 2 weeks; a normal initial LP does not exclude GBS.

Evidence-Based Immunotherapy

IVIG ( 2 g/kg 2\text{ g/kg} 2 g/kg divided over 5 days) OR PLEX (5 plasma exchanges) represents first-line therapy. Treatment must be initiated promptly upon diagnosis to halt immune axotomy.

Cochrane Evidence on Equivalence: Multiple large randomized multicenter trials proved that IVIG and PLEX are therapeutically equivalent in accelerating time to independent ambulation and weaning from mechanical ventilation. However, combining PLEX followed immediately by IVIG confers no additive efficacy while doubling cost and complication rates.

Important

Corticosteroids are not effective treatment for GBS and should not be prescribed to treat the neuropathy. This does not prohibit steroids for a separate compelling indication. IVIG or plasma exchange is used according to severity, timing, and specialist assessment; routine sequential combination has not shown added benefit.

Airway Management & The Lethal Succinylcholine Caveat

When endotracheal intubation is required in acute neuromuscular respiratory failure, rapid sequence intubation ( R S I RSI RS I ) must be executed with specialized pharmacological precautions.

Caution

Avoid succinylcholine in GBS and established denervation because of potentially fatal hyperkalemia. Choose a nondepolarizing agent and dose suited to the specific neuromuscular disease and airway context. Myasthenia can markedly increase sensitivity to nondepolarizing blockade. Sugammadex dosing depends on the agent and depth of blockade, and reversal does not guarantee a safe airway or extubation; continue the difficult-airway oxygenation and rescue plan.

Critical Illness Polyneuropathy (CIP) vs. Critical Illness Myopathy (CIM)

In the neuro-ICU and medical-surgical ICU, patients with prolonged sepsis, multi-organ dysfunction syndrome ( M O D S MODS MO D S ), A R D S ARDS A R D S , and protracted mechanical ventilation frequently develop acquired neuromuscular weakness termed Intensive Care Unit-Acquired Weakness ( I C U A W ICUAW I C U A W ). Distinguishing between Critical Illness Polyneuropathy ( C I P CIP C I P ) and Critical Illness Myopathy ( C I M CIM C I M ) requires comprehensive clinical and electrodiagnostic testing ( E M G / N C S EMG/NCS EMG / NCS ).

Diagnostic Domain Critical Illness Polyneuropathy (CIP) Critical Illness Myopathy (CIM)

Primary Pathophysiology Primary distal axonal sensory-motor degeneration; microvascular ischemia of endoneurial capillaries Non-necrotizing myopathy with selective loss of thick myosin filaments (myosin-loss myopathy)

Key Risk Factors Severe sepsis, multi-organ failure, endotoxemia, prolonged systemic inflammation Sepsis PLUS corticosteroid therapy and prolonged neuromuscular blockade (e.g., cisatracurium)

Clinical Neurological Exam Distal flaccid tetraparesis; distal sensory loss; absent deep tendon reflexes; facial sensation spared Diffuse flaccid quadriparesis ( proximal > distal ); sensation completely intact ; variable/diminished DTRs

Sensory Nerve Action Potentials (SNAPs) Markedly reduced or absent amplitudes (axonal sensory loss) Normal SNAP amplitudes and normal sensory conduction velocities

Compound Muscle Action Potentials (CMAPs) Markedly reduced amplitudes; normal or mildly prolonged duration Markedly reduced amplitudes; markedly prolonged CMAP duration (> 10 ms)

Needle Electromyography (EMG) Fibrillations and positive sharp waves; neurogenic high-amplitude polyphasic motor units Fibrillations and positive sharp waves; myopathic short-duration, low-amplitude motor units

Direct muscle stimulation Relatively preserved muscle excitability can support neuropathy Reduced muscle excitability can support myopathy; interpret with specialist technique and other findings

Prognosis & Functional Recovery Protracted recovery over months to years; incomplete recovery common due to slow axonal regeneration ( 1 mm/day 1\text{ mm/day} 1 mm/day ) Favorable recovery over weeks to months as muscle proteins resynthesize; better long-term functional independence

Plan durable immunotherapy: Corticosteroids can transiently worsen weakness. Coordinate their timing and dose with neuromuscular specialists and the rapid treatment provided by PLEX or IVIG, rather than using high-dose steroids as unsupported sole rescue treatment during severe respiratory crisis. The plan is individualized, not a prohibition on every earlier steroid dose.

Rapid disease treatment in myasthenic crisis: Plasma exchange or IVIG is selected promptly with neuromuscular specialists. IVIG is commonly given as a total 2 g/kg over two to five days, adjusted to the clinical context; assess thrombosis, kidney, volume, and infusion risks. Plasma exchange requires an access and hemodynamic plan and can remove therapeutic medications. Response is not guaranteed within a fixed number of hours. Treat the precipitating infection or other trigger, arrange nutrition and airway clearance, and reassess swallowing and respiratory strength before extubation. Selected patients may tolerate noninvasive support, but bulbar failure, secretion burden, exhaustion, or rapid deterioration favors intubation.